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Purpura fulminans due to MSSA Toxic Shock Syndrome
Leah Grant MD and Rachel Plotinsky MD
Introduction
Purpura fulminans is a rare and serious complication 
of an acute infectious process, characterized by large 
purpuric skin lesions, fever, hypotension, and DIC. The 
most common infectious cause of purpura fulminans
is meningococcal disease, though few case reports in 
the literature describe Staph aureus as a causative 
organism.​
Case Report
• A 53 year-old woman with a history of heart 
block s/p pacemaker placement in 2002 presented to 
the ED with nausea, vomiting, fevers, chills, diffuse 
muscle pain and a syncopal episode.
• She was found to have multi-organ dysfunction on 
labs, including AKI and thrombocytopenia. On hospital 
day 2, she developed acrocyanosis. She became febrile 
& hypotensive requiring transfer to the ICU for 
vasopressor support. Blood cultures were obtained. 
She was started on broad-spectrum antibiotic therapy​.
• Because of the patient’s thrombocytopenia and overall 
critical illness, the differential diagnosis included TTP, 
DIC, HUS, drug-induced hemolytic anemia, or a rare 
disorder called catastrophic antiphospholipid antibody 
syndrome (CAPS).
• She was treated empirically for CAPS with plasma 
exchange, heparin, and steroids.
• Blood cultures were positive for methicillin-sensitive 
Staph aureus, and antibodies for CAPS were negative.
• Antibiotic therapy was narrowed to Cefazolin, and her 
infected pacemaker was extracted. 
• She required bilateral below-the-knee amputations as 
well as multiple finger amputations due to necrosis.
• Most likely diagnosis is purpura fulminans from MSSA 
toxic shock syndrome.​
Discussion
• In acutely ill patients with skin findings described in 
this case as well as multi-organ dysfunction, there are 
several life-threatening diagnoses which must be 
recognized and treated promptly​.
• Given the 50% risk of mortality even with prompt 
initiation of therapy for CAPS, we did not delay in 
starting this patient on plasma exchange​.
• In purpura fulminans, the clotting cascade is disrupted 
by bacterial endotoxins and inflammatory cytokines, 
leading to a procoagulant and anticoagulant state, 
which in turn leads to intravascular thrombosis and 
hemorrhagic infarction of the skin​.
• A report of 5 cases of purpura fulminans caused by 
MSSA TSS was published in the journal Clinical 
Infectious Diseases in 2005, and the isolated strains
of MSSA were noted to 
produce higher-than-
expected levels of 
endotoxins normally 
associated with TSS. 
• Treatment of purpura
fulminans from MSSA 
TSS is antibiotic 
therapy. 
• It remains a rare and 
serious complication 
of acute infection 
which providers 
should keep on their 
differential of life-
threatening illnesses 
associated with 
thrombocytopenia 
and purpuric skin 
lesions.
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